Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR).

10 Feb 2011

Genmed announces Suprafen drug registration with Dutch MEB

Genmed Holding Corp. has announced its next generic drug registration. The Company will file it's dossier for the drug Suprafen, otherwise known as Ibuprofen, with the Dutch Medicines Evaluation Board in the coming months. Suprafen is a non-steroidal anti-inflammatory as well as an analgesic.

9 Feb 2011

Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2010.

8 Feb 2011

AmerisourceBergen first quarter revenues increase 3% to record $19.9 billion

AmerisourceBergen Corporation today reported that in its fiscal year 2011 first quarter, ended December 31, 2010, diluted earnings per share were $0.57, a 10 percent increase. Revenue in the quarter was a record $19.9 billion, up 3 percent.

4 Feb 2011

Generic drugs to treat hypertension, heart failure could help NHS save £200 million

Using a generic drug to treat hypertension and heart failure, instead of branded medicines from the same class, could save the UK National Health Service (NHS) at least £200 million in 2011 without any real reduction in clinical benefits.

3 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

PCMA finds Ohio's Medicaid program can save $135 million over the next decade

Ohio's Medicaid program could cost taxpayers an additional $1.6 billion next year, a 49 percent jump in the state's share of costs for the health care program covering more than 2 million poor and disabled Ohioans, according to new information released by the Governor's Office of Health Transformation.

1 Feb 2011

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Johnson & Johnson's Tibotec Pharmaceuticals unit on Thursday announced it had granted multiple licenses to generic drug manufacturers "to provide copies of [the experimental HIV/AIDS drug rilpivirine hydrochloride] TMC278 in sub-Saharan Africa, India and parts of Asia if it's approved by regulators," Bloomberg Businessweek reports.

1 Feb 2011

Generics companies weigh in on biological drugs, the Wall Street Journal reports

Generic drug makers are expecting copies of complex biological drugs to become a multi-billion dollar market in the near future.

1 Feb 2011

First Edition: January 31, 2011

KHN staff writers Marilyn Weber Serafini and Julie Appleby report: "Financially strapped governors, Congress and the Obama administration could be headed for a showdown over the Medicaid health care program that covers 48 million poor, disabled and elderly people nationwide".

31 Jan 2011

Endo Pharmaceutical partners receive Paragraph IV Certification for generic version of LIDODERM

Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, have received a Paragraph IV Certification Notice from Mylan Technologies advising of the filing of an Abbreviated New Drug Application for a generic version of LIDODERM.

31 Jan 2011

Teva announces acquisition of Corporación Infarmasa

Teva Pharmaceutical Industries Ltd. announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments.

27 Jan 2011

Anapharm Europe, PharmaNet officially terminate joint venture

PharmaNet Development Group, and Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010.

27 Jan 2011

Teva, APP enter agreement for launch of generic Gemzar

Teva Pharmaceutical Industries Ltd. and APP Pharmaceuticals, Inc. announced today the commercial launch of Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials, the generic version of Gemzar®, in the United States, pursuant to a commercialization, manufacture and supply agreement signed by the two companies.

26 Jan 2011

Teva Pharmaceutical announces entry into new three-year credit facility

Teva Pharmaceutical Industries Ltd. announced today that it has entered into a new three-year, $1.5 billion unsecured revolving credit facility, which replaces and expands existing credit lines at terms that are more favorable to Teva.

24 Jan 2011

Reducing generic prices will not result in pharmacy shortages: Study

A University of British Columbia study shows that there are enough pharmacies situated throughout Ontario communities to absorb many closures without negatively affecting geographical accessibility for residents. The research suggests concerns that reducing generic pricing could result in pharmacy shortages are unfounded.

20 Jan 2011

Research roundup: Racial disparities in cancer and other care, nursing home closures, extending drugmakers' exclusivity

Journal of the National Cancer Institute: Projections Of The Cost Of Cancer Care In The United States: 2010-2020 - "By combining cancer prevalence with average annual costs of cancer care by phase of care and tumor site for 13 cancers in men and 16 cancers in women" and "all cancer sites combined," the authors project there will be just over 18 million cancer survivors in 2020 compared to 13.8 million survivors in 2010.

14 Jan 2011

Sleep medications increase risk for nighttime falls and potential injury

Adults who take one of the world's most commonly prescribed sleep medications are significantly more at risk for nighttime falls and potential injury, according to a new study by the University of Colorado at Boulder.

14 Jan 2011

US most susceptible to brand erosion post patent expiry

On average, small molecule brands in the US experienced the greatest degree of brand erosion following patent expiry and exposure to direct generic competition, according to a new report from independent market analyst, Datamonitor.

12 Jan 2011

New study finds extending term of exclusive access can lead to higher drug costs in short term

A new study in the January 2011 issue of Health Affairs is the first to calculate the financial and social costs of limiting access to trial data — and finds that extending the term of exclusive access will lead to higher drug costs in the short term but also to more than 200 extra drug approvals and to greater life expectancy in the next several decades.

10 Jan 2011